FACTIVE

Compare FACTIVE  to:
Compare
Compare

Generic Name for FACTIVE

Gemifloxacin mesylate 320mg; scored tabs.

Legal Classification:

Rx

Pharmacological Class for FACTIVE

Quinolone.

Manufacturer of FACTIVE

Oscient Pharmaceuticals

Indications for FACTIVE

Susceptible infections including acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.

Adult dose for FACTIVE

≥18yrs: Swallow whole. Take with full glass of water. 320mg once daily. Bronchitis: treat for 5 days. Community-acquired pneumonia: treat for 5 or 7 days (based on susceptible bacteria; see literature). Renal impairment and dialysis: CrCl≤40mL/min: 160mg every 24 hours.

Children's dosing for FACTIVE

<18yrs: not recommended.

Warnings/Precautions for FACTIVE

Increased risk of tendinitis and tendon rupture esp. in patients >60yrs, or those with kidney, heart or lung transplants. Maintain adequate hydration. Discontinue if rash, other signs of hypersensitivity, phototoxicity, CNS stimulation, or tendon pain, inflammation, or rupture occurs. CNS disorders (eg, epilepsy). Avoid sunlight, UV light. History of QTc prolongation, electrolyte disorders (eg, hypokalemia), or proarrhythmic conditions. Pregnancy (Cat.C). Nursing mothers: not recommended.

Interactions for FACTIVE

Avoid drugs that prolong QTc interval (eg, Class IA or Class III antiarrhythmics, erythromycin, antipsychotics, tricyclics). Separate dosing of magnesium- or aluminum containing antacids and didanosine, sucralfate, iron, zinc, other metal cations (do not take within 3 hours before or 2 hours after gemifloxacin). Potentiated by probenecid. Increased risk of tendinitis and tendon rupture with corticosteroids. Monitor warfarin.

Adverse Reactions for FACTIVE

GI upset, rash, urticaria, headache, abdominal pain, dizziness, elevated liver enzymes, photosensitivity, tendinitis/rupture; rarely: convulsions.

How is FACTIVE supplied?

Tabs—5, 7

Related Disease:

Bronchitis, chronic
Infections, bacterial~systemic antiinfectives
Pneumonia

Related Resources

Tygacil labeling updated to include increased mortality risk

September 01, 2010

The FDA is reminding healthcare professionals that intravenous Tygacil (tigecycline, from Pfizer) can increase mortality risk in the treatment of serious bacterial infections.

Phase 3 study of torezolid for acute bacterial skin and skin structure infections

August 30, 2010

Trius Therapeutics announced the initiation of its Phase 3 study of oral torezolid phosphate for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

FDA warns of eosinophilic pneumonia risk with Cubicin

July 29, 2010

The FDA has notified healthcare professionals and patients about the potential for developing eosinophilic pneumonia while receiving the antibiotic Cubicin (daptomycin, from Cubist).

FDA warns of counterfeit Tamiflu product

June 18, 2010

The FDA has warned consumers about a potentially harmful product represented as "Generic Tamiflu" sold over the Internet.

Claris Lifesciences' intravenous medications recalled

June 01, 2010

The FDA has notified healthcare professionals not to use the intravenous medications, metronidazole, ciprofloxacin and ondansetron manufactured by Claris Lifesciences due to contamination.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions